BrainScan

BrainScan EBITDA Growth YoY

The Year-over-Year EBITDA Growth of BrainScan (BSN.WA) as of Oct 30, 2026 is 42.63 %. In the previous year, Year-over-Year EBITDA Growth was -133.86 % — a change of -131.85% (higher).

EBITDA Growth YoY

42.63 %

YoY

-131.85%

Last updated:

Year-over-Year EBITDA Growth of BrainScan is 2025 42.63 % . Year-over-Year EBITDA Growth of BrainScan was 2024 -133.86 % . It decreases by -131.85% higher compared to the previous year.

The BrainScan EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2023
-59.27 PLN
Jan 1, 2024
-133.86 PLN
Jan 1, 2025
42.63 PLN
The BrainScan EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
42.63 %-131.85%
-133.86 %+125.86%
-59.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrainScan Stock analysis

What does BrainScan do? BrainScan SA generates revenue through its flagship product, the BrainScan CT system, which is used by medical facilities to optimize brain imaging diagnostics. The system delivers head tomography analysis results in under three minutes, identifying pathologies like tumors and hemorrhages through AI-driven deep learning. Hospitals and clinics purchase the system to accelerate diagnostic processes and improve treatment decision-making. The company's AI technology enables automatic patient triage, enhancing the efficiency of medical interventions. The BrainScan CT system is designed for use in healthcare settings where rapid diagnosis is critical, such as emergency departments and specialized neurology clinics. Medical institutions in Poland and potentially other European markets are the primary customers, leveraging the system's ability to shorten the time between examination and treatment initiation. The company's focus on AI-powered diagnostics positions it as a solution for facilities seeking to modernize their imaging workflows. BrainScan SA's revenue model relies on the sale of its AI diagnostic system to healthcare providers, with the BrainScan CT system being the core product. The system's unique value proposition lies in its speed and accuracy, offering results faster than traditional methods. By automating the analysis of brain imaging, the system reduces the workload on radiologists and improves patient outcomes through timely interventions. BrainScan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrainScan stock

Year-over-Year EBITDA Growth of BrainScan is 42.63 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth BrainScan since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's BrainScan historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — BrainScan

All Key Metrics — BrainScan